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Summary
We have inactivated pRb, p107, and p130 in astrocytes by transgenic expression of T121 (a truncated SV40 T antigen) under
the GFAP promoter. Founder mice died perinatally with extensive expansion of neural precursor and anaplastic astrocyte
populations. In astrocytes, aberrant proliferation and extensive apoptosis were induced. Using a conditional allele of T121,
early lethality was circumvented, and adult mice developed high-grade astrocytoma, in which regions of decreased apopto-
sis expressed activated Akt. Indeed, astrocytoma development was accelerated in a PTEN/, but not p53/, background.
These studies establish a highly penetrant preclinical model for astrocytoma based on events observed in the human
disease and further provide insight into the role of PTEN mutation in astrocytoma progression.
Introduction astrocytoma/glioblastoma include p53 (30%) and PTEN (50%)
loss-of-function and EGFR (30%) gain-of-function mutations
(Reilly and Jacks, 2001; Louis and Cavenee, 2001; Maher et al.,Astrocytomas are divided into three grades: astrocytoma (WHO
2001). Given the high frequency with which pRb function isgrade II), anaplastic astrocytoma (WHO grade III) and glioblas-
impaired in human astrocytoma, we tested the impact of inacti-toma (WHO grade IV) (Maher et al., 2001; Reilly and Jacks,
vating this pathway specifically in astrocytes of genetically engi-2001; Louis and Cavenee, 2001). Primarily because of its diffuse
neered mice. T121, a truncated SV40 T antigen mutant, wasnature, there is no effective treatment for astrocytoma, and little
used to dominantly inactivate pRb, p107, and p130 (referred tois known about the mechanism(s) by which it develops. For
collectively as Rbf) in astrocytes. We previously showed thatexample, the susceptible target cell(s) is not clear, cause and
transgenic expression of T121 in brain choroid plexus epithelialeffect relationships between genetic lesions and cell/tissue re-
cells induced aberrant proliferation and apoptosis, predisposingsponses are largely undetermined, and the molecular and cellu-
them to tumorigenesis (Symonds et al., 1994; Lu et al., 2001).lar basis for progression from low- to high-grade malignancy is
Here, we test whether astrocytes respond similarly to Rbf inacti-not understood. Experimental animal models are required to
vation, whether a defect in this pathway predisposes to astrocy-
understand the complexities of this disease and to develop toma, and whether mutations in p53 or PTEN cooperate with
reasonable therapies for its treatment. Rbf inactivation in astrocytoma development.
70% to 80% of human grade III and IV gliomas carry muta-
tions in the pRb pathway, including INK4a locus mutation (33%– Results
68%), direct Rb inactivation (20%–30%) or CDK4 overexpres-
sion (10%–15%) (Henson et al., 1994; Ueki et al., 1996). Within Astrocyte-specific pRbf inactivation causes
tumors, such mutations are generally mutually exclusive, sup- widespread brain abnormalities
porting the idea that these factors function within the same A transcriptional regulatory fragment from the human glial fibril-
lary acidic protein (GFAP) gene was used to direct T121 expres-pathway (Ueki et al., 1996). Other genetic alterations common in
S I G N I F I C A N C E
Astrocytoma, rarely amenable to standard therapies, is the most common primary human brain tumor. Mutations in the pRb pathway
(70%–80%) and in PTEN (50%) are common and often concurrent in these tumors. Yet, roles for these pathways in astrocytoma
development have not been explored in vivo. We show that pRb pathway inactivation in transgenic mouse astrocytes predisposes
to the development of high grade astrocytomas. Mice that further carry a single null PTEN allele develop disease with shortened
latency, providing evidence that PTEN mutation is causal in astrocytoma development, but may require collaborating events. This
mouse model provides a tool for understanding astrocytoma development and may also be useful in preclinical testing of therapeutic
approaches.
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astrocytoma-like cells (Figure 3A), but was absent from the
periventricular cells (Figure 3D). Neither population expressed
synaptophysin, a marker of mature neurons (not shown). Peri-
ventricular cells were characteristic of neural progenitors based
on positivity for Tuj-1 and PSA-NCAM (Figures 3C and 3F,
respectively) (Doetsch et al., 1997) and the absence of S-100
(glial-specific) and vimentin (glial progenitor-specific) (not
shown). Tuj-1 and PSA-NCAM were not expressed in the ana-
plastic GFAP-positive cells (not shown), consistent with an
astrocytic phenotype for these cells.
To determine whether both abnormal cell populations were
induced by intrinsic inactivation of the pRb pathway, brain sec-
tions were analyzed for T121 expression by immunohistochemis-
try. Consistent with the use of the GFAP promoter to drive
transgene expression, T121 was expressed in diffuse anaplastic
cells (Figure 3B), but not in the majority of primitive periventricu-
lar cells (Figure 3E). Colocalization immunofluorescence
showed that most T121-expressing cells also expressed GFAP,
confirming their astrocytic origin (Figures 3G–3J). Since T121
was not detected in the abnormal periventricular regions, the
mechanism by which these cells are affected is currently un-
Figure 1. Transgene design clear. Possible explanations include T121 expression at a prior
A: In the GFAP-T121 transgene, a 2.2 Kb human GFAP containing transcrip- differentiation stage, dedifferentiation of T121-expressing astro-
tional regulatory signals (dark gray box) was linked to the SV40 early region cytes, or non-cell autonomous effects produced by aberrant
carrying a deletion of the small t antigen-specific splice signal and a deletion
astrocytes. Developmental studies will be required to distinguishthat results in a truncation of large T antigen at aa 121. T121 reading frames
these possibilities.(light gray boxes), SV40 large T antigen intron (sp), and the SV40 early region
polyA signal (pA) are indicated. The T121 protein binds to and inactivates
pRb, p107, and p130. B: In the GZT121 transgene a LacZ cassette flanked by Rbf inactivation induces astrocyte proliferation
lox P sites was inserted between GFAP regulatory signals and the T121 gene. and apoptosis
Due to the stop signals in the LacZ gene, T121 expression is not possible
We previously demonstrated that pRbf inactivation by T121 ex-until the cassette is deleted by Cre-mediated recombination. When the
pression in choroid plexus epithelial (CPE) cells induced bothtransgene is integrated as a multicopy head-to-tail array (as is typical),
recombination can reduce the original multicopy (n) transgene to a single proliferation and apoptosis. To determine whether similar re-
copy. The probe for Southern hybridization and primers for PCR assays to sponses occurred in anaplastic T121-expressing astrocytes, pro-detect the Cre-mediated deletion are indicated.
liferation was assessed using immunofluorescence to detect
coexpression of T121 and PCNA (Figures 4A–4D and 4G). Among
the T121-positive cells, 32%–38% also expressed PCNA, while
only 6%–8% of T121-negative cells from the same region ex-sion in transgenic mice (Figure 1A). This fragment has been
pressed PCNA. In a similar location of age-matched nontrans-shown to drive transgene expression within the CNS astrocyte
genic brains, 1% of the cells were PCNA-positive (Figure 4G).lineage (e.g., Brenner et al., 1994; Holland and Varmus, 1998).
The moderate proliferation increase in T121-negative cells ofOf 13 TgGFAPT121 transgenic founder mice produced, 10 devel-
transgenic mice likely indicates the presence of reactive gliaoped severe brain abnormalities (hydrocephalus and/or macro-
responding to extensive brain abnormalities.cephaly) and died by postnatal (p) days 7–9 (see Supplemen-
To determine the apoptotic rate, TUNEL analysis was per-tal Table S1 at http://www.cancercell.org/cgi/content/full/1/1/
formed on age-matched transgenic and nontransgenic brains157/DC1). Other organs appeared normal, consistent with the
(Figures 4E, 4F, and 4H). 6% to 7% of the cells in T121-expressingspecificity of the GFAP promoter. Similar abnormalities were
regions were apoptotic, while such cells were rarely detectedpresent in the 6 brains examined. Brains were hypercellular and
in any region of nontransgenic brains (with the exception of thecontained two morphologically distinct abnormal cell popula-
rostral migratory route [data not shown and Kirschenbaum ettions (Figure 2). One poorly differentiated population was lo-
al., 1999; Brunjes and Armstrong, 1996]) (Figure 4H). By compar-cated in the periventricular region of the lateral ventricles and
ison, 1.7%–2% of the cells were apoptotic in abnormal T121-resembled persistent germinal matrix (Figure 2D, e.g., region I
negative periventricular regions (Figure 4H). Thus in astrocytes,and 2E). These cells had small, rounded to angular, densely
as in CPE, pRbf inactivation induces extensive proliferation andhyperchromatic nuclei with scant cytoplasm (Figure 2E). A sec-
apoptosis.ond aberrant cell population was present diffusely throughout
the brain (Figure 2D; e.g., region II) and was composed of cells
Inducible astrocyte Rbf inactivation predisposes adultwith larger, more irregular, sometimes oval nuclei with vesicular
mice to high grade astrocytomachromatin and occasionally visible small cell processes (Figure
Since TgGFAPT121 mice died perinatally, we were unable to2F), thus resembling developing glial cells and the cells of ana-
determine whether increased astrocyte proliferation and apo-plastic astrocytic neoplasms (Kleihues and Cavenee, 2000).
ptosis could lead to tumorigenesis in adult mice. To addressTo investigate cellular origins, brain sections were analyzed
this issue, we generated transgenic mice (TgGZT121) in whichfor the presence of specific markers. GFAP, a component of
the astrocyte intermediate filament, was detected in the diffuse T121 expression could be induced by Cre-mediated deletion of
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Figure 2. Astrocyte-specific inactivation of the Rb pathway induces extensive brain abnormalities
Representative brain histopathology of the TgGFAP-T121 transgenic founder mice (D–F) is shown in comparison to an age-matched nontransgenic control
(A–C) at p7. Boxes indicated in A and D are shown at high power in the remaining panels; region I in B and E and region II in C and F. These views are
representative of the observed abnormalities described in the text. Region I is present within a large abnormal periventricular area (compare A and D, B
and E). Region II is representative of the hypercellularity found diffusely throughout the brain (compare A and D, C and F). Perineuronal (F, red arrow) and
perivascular satellitosis and pathological landmarks of human astrocytoma cells are common in this population. V: lateral ventricle. Bar  200 m in A and
D; 15 m in B, C, E and F.
an upstream lac Z reporter/stop signal (Figure 1B). Four inde- of compound TgGZT121;TgactinCre mice and their T121 trans-
gene-positive offspring (hereafter referred to as TgG(Z) T121).pendent lines of TgGZT121 mice were produced and shown to
express similar patterns of -galactosidase in glial-rich regions However, levels of expression per cell appeared significantly
lower than in TgGFAPT121 founder mice (Figure 5B, compareof the brain, including dentate gyrus, cerebral cortex, and hypo-
thalamus (not shown). As anticipated, TgGZT121 mice did not panels b and d with c), possibly owing to the reduction in trans-
gene copy number. Surprisingly, despite T121 expression, allexpress T121 in the brain (Figure 5B, panel a) or in other organs
(not shown), and they remained normal to at least 17 months TgG(Z)T121 mice (40) survived beyond the perinatal stage
(Supplemental Table S1 and Figure 5C), an effect which could beof age (Figure 5C and Supplemental Table S1 at http://www.
cancercell.org/cgi/content/full/1/1/157/DC1). due to the low levels of T121 expressed and/or genetic modifiers
introduced by the FVB background of the TgactinCre mice.Originally, we intended to test whether T121 expression could
predispose to astrocytoma by somatic introduction of Cre using Analysis of p7 compound mice showed that increased periven-
tricular cellularity was indeed present, but was not as severeviral vectors. While this will ultimately prove to be an important
strategy, we found that the early lethality observed in founder as in the TgGFAPT121 founder mice described above (Figure 5B,
compare panels e–g). Reduced severity of this phenotype likelymice could be circumvented even if Cre was introduced during
development. Two independent lines of TgGZT121 mice were facilitated longer survival. As in TgGFAPT121 mice, increased
cellularity was also observed throughout the p7 brain (e.g., Fig-crossed to TgactinCre mice, which express Cre under the
-actin promoter beyond the 64-cell stage (Lewandoski and ure 5B), although mitotic figures and cytological irregularities
were less prominent. Beyond 1–3 months of age, TgG(Z)T121Martin, 1997). The crosses produced all expected genotypes
at normal Mendelian frequencies (data not shown). Furthermore, mice showed signs of morbidity including bulging crania and
weight loss. The mice became terminally ill by 5–8 months ofboth Southern hybridization analysis of tail DNA (Figure 5A, left
panel) and PCR analysis of brain tissue (Figure 5A, right panel) age due to the presence of malignant anaplastic astrocytomas
(Supplemental Table S1 and Figure 5C).demonstrated that the lacZ cassette was efficiently deleted in
doubly transgenic mice. Southern analysis also showed that Of 40 brains examined histologically, all contained moderate
to marked increases in cellularity that involved essentially allrecombination facilitated a reduction in the copy number, appar-
ently to a single copy, as expected if the transgene had inserted regions (some regions more markedly hypercellular than others),
including the brain stem and cerebellum (compare Figures 6Ain a tandem head-to-tail array (Figure 5A, left, compare lanes
2 and 3; Lakso et al., 1996; Lewandoski and Martin, 1997). and 6B). In the cerebral cortex, the infiltration pattern was char-
acteristic of astrocytoma, including perineuronal and perivascu-Consistent with the specificity of the GFAP promoter associ-
ated with the GZT121 transgene, immunohistochemical analysis lar satellitosis (Figures 6C and 6D, respectively) as well as sub-
pial spread (not shown). These cytological and architecturalrevealed that T121 was expressed diffusely throughout the brains
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Figure 3. Two distinct brain cell populations are affected
Immunohistochemical assays (A–F; blue stain  positive) show that diffuse cells (region II, Figure 2) express the astrocytic marker GFAP (A) while abnormal
periventricular cells (region I, Figure 2) do not (D). T121 is also expressed in diffuse (B) but not periventricular (E) cells. Abnormal periventricular cells express
the neural precursor markers Tuj1 (C) and PSA-NCAM (F). Black bar  20 M. Immunofluorescence staining of diffuse region II cells shows colocalization of
GFAP and T121 in most T121-expressing cells (J; H and I merged). T121 is detected with a fluorescein conjugated antibody (H, green) and GFAP with a rhodamine-
conjugated antibody (I, red). Nuclei are stained with DAPI (G, blue). White bar  10 M.
features are consistent with a diffusely infiltrative, malignant TuJ-1, and PSA-NCAM (not shown), confirmed the astrocytic
phenotype of tumor cells. Currently, 44 mice from 2 independentastrocytic glioma, with the widespread involvement resembling
the extremely infiltrative human condition of gliomatosis cerebri TgG(Z) T121 lineages have developed astrocytomas (Supple-
mental Table S1).(Kleihues and Cavenee, 2000). The hyperchromatic nuclei, hy-
percellularity, and mitotic activity would be most consistent with
a diagnosis of anaplastic astrocytoma (WHO grade III), with the Akt kinase is regionally activated during
astrocytoma developmentcells appearing less differentiated than those found in diffuse
astrocytomas (grade II), but there is neither the microvascular The long latency between T121 expression (by p7) and the devel-
opment of life-threatening astrocytomas (generally 100 days)proliferation nor the necrosis necessary for a diagnosis of glio-
blastoma (grade IV; Kleihues and Cavenee, 2000). Marker stud- indicates that additional events subsequent to pRbf inactivation
may be required. In human gliomas, EGF and PDGF receptories are also consistent with these conclusions. Large popula-
tions of cells expressed GFAP (Figure 6F), as is often observed mediated Ras/MAP kinase and PTEN regulated PI3 kinase/Akt
signaling cascades are frequently altered, correlating with tumorin human astrocytomas (Kleihues and Cavenee, 2000). At times,
anaplastic cells didn’t stain positively for GFAP, or the exact progression (Reilly and Jacks, 2001; Louis and Cavenee, 2001;
Maher et al., 2001). Thus, we examined tumors for evidence oforigin of positive signals was difficult to determine. In these
cases, staining for S-100 (Figure 6H), a nuclear glial marker altered regulation of these pathways.
Activation of Akt kinase by phosphorylation at ser 473 is(Kimura et al., 1986) along with the absence of synaptophysin,
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Figure 4. Inactivation of the Rb pathway in astrocytes induces aberrant proliferation and apoptosis
The brains of three independent TgGFAP-T121 founder mice (F0 1–3, Supplemental Table S1 at http://www.cancercell.org/cgi/content/full/1/1/157/DC1)
were analyzed for proliferation (A–D and G) and apoptosis (E, F, and H). Proliferation rates were determined for T121-expressing and nonexpressing cells
in regions of the brain that harbored anaplastic cells. Cells were doubly stained for T121 (fluorescein/green; B) and PCNA (rhodamine/red; C) using
immunofluorescence. Using the merged image (D) the percentage of PCNA positive cells expressing T121 (e.g., arrow heads) or not (e.g., arrow) was
calculated (G). Nuclei were stained with DAPI (blue; A). In comparable regions of a p7 nontransgenic control brain, PCNA positive cells were only rarely
detected (1%; C in G). The TUNEL assay (positive signal  brown) detected apoptotic cells in regions containing anaplastic astrocytes (E) or periventricular
neural precursors (F). The percentages of apoptotic cells relative to total cells in the regions examined were calculated (H). Only rare apopotic cells
(0.1%) were detected in all comparable regions from a p7 nontransgenic brain. For both proliferation and apoptosis assays, 5 fields (1000 total cells)
were assessed for each brain. Error bars in G and H indicate the standard deviation among fields. White bar  20 M; black bar  40 M.
positively regulated by PI3 kinase and PDK1, and negatively pared with cultures from normal control brains, while the overall
level of Akt was unchanged (Figure 7K; Table 1).regulated by PTEN (Datta et al., 1999 and references therein).
Akt activation has been shown to protect cells from apo-Thus, we determined whether Akt was activated in astrocytomas
ptotic stimuli (Stambolic et al., 1998; Datta et al., 1999 andby immunohistochemistry using an antibody specific for P Ser473-
references therein). Given the high level of astrocyte apoptosisAkt. 72% of the astrocytomas (13 of 18; Table 1) demonstrated
induced by Rbf inactivation, we performed TUNEL assays toregional expression of activated Akt (Figure 7A). Such regions
determine whether tumor regions expressing activated Aktwere absent from age-matched control TgGZT121 and Tg
showed evidence of altered apoptotic rates. Indeed, the apopto-actinCre mice (data not shown). Akt activation was not a direct
sis level was greatly reduced in Akt active regions comparedeffect of T121 expression, and likely represents a secondary event
to surrounding tissue in 3 of 3 mice examined (e.g., comparein tumorigenesis. Activated Akt was undetectable in young
Figures 7C and 7G). Proliferating astrocytes were present atTgG(Z)T121 brains (3 of 3 mice tested at p7–10; e.g., Figure 7I) similar frequencies in regions with and without activated Aktand in TgGFAPT121 founder brains (5 of 5 mice tested, p7–9), expression (e.g., compare Figures 7D and 7H). Thus, Akt activa-
despite widespread expression of T121 (Figure 7J). Furthermore, tion may provide a selective advantage to astrocytoma cells
when mice were terminally ill, Akt was activated regionally (e.g., initiated by Rbf inactivation, at least in part by reducing apo-
compare Figures 7A and 7E from the same brain), while T121 ptosis.
was expressed throughout the brain (Figures 7B and 7F). We also investigated the phosphorylation status of p42/
To confirm the specificity of immunohistochemical assays, p44 MAP kinase and Erk1 and 2 by immunohistochemistry. In
immunoblotting was used to assess Akt and PSer473-Akt expres- rodents, Erk 1 and 2 are activated by EGF and PDGF receptor/
sion in primary astrocytes from TgGZT121 control and TgG(Z) Ras signaling cascades by phosphorylation of Thr183 and
T121 astrocytoma-containing brains. Consistent with the immu- Tyr185 (Schlessinger, 2000 and references therein). Of 18 astro-
nohistochemical results, most tumor cell preparations ex- cytoma-containing brains examined, only 2 showed evidence
of Erk 1,2 phosphorylation; neither expressed activated Akt (Ta-pressed a significantly higher level of phosphorylated Akt com-
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Figure 5. Characterization of TgG(Z) T121 mice
A: Southern blotting analysis of tail DNA (left
panel) indicates that the expected deletion of
the lac Z cassette along with a reduction in trans-
gene copy number occurred in TgG(Z) T121 mice
(lane 2) compared with TgGZT121 DNA (lane 3).
No specific signal was present in control  -actin
Cre DNA (lane 1). The probe was derived from
the T121 gene (see Figure 1B). All DNAs contained
similar signals when hybridized with the PTEN con-
trol probe. PCR analyses on brain DNA samples
(right panel) confirm the removal of the lacZ cas-
sette in TgG(Z)T121 brains (lane 2, primers 1 and
3). Primer sequences 1, 2, and 3 are mapped in
Figure 1B. The specificity of the pimers is indi-
cated to the right of the panel. Lanes 1,  -actin
Cre; lanes 2, TgG(Z)T121; lanes 3, TgGZT121. B: Im-
munohistochemical detection of T121 (panels
a–d; positive signal  blue) shows T121 expression
in adult (b) and p7 (d) TgG(Z) T121 brains, but
not in brains of parental adult TgGZT121 (a) or
-actin Cre (not shown) mice. Staining under the
same conditions of a p7 TgGFAP-T121 transgenic
founder brain is shown for comparison in panel
c. Hypercellularity in the periventricular regions
was observed in H&E-stained p7 TgG(Z) T121
brains (g) compared to a p7 nontransgenic con-
trol (e), but was less extensive compared to that
of p7 TgGFAP-T121 founder mice (f). Bar  20 M
in panels a–d, 30 M in e–g. C: Astrocytoma-free
survival of mice is plotted as a function of time.
All TgG(Z) T121 mice died of anaplastic astrocy-
toma, while all parental uninduced TgGZT121
mice survived beyond 400 days, and none de-
veloped astrocytoma (•; n40). PTEN, but not
p53, mutation cooperates with pRbf inactivation
in the development of astrocytoma. Each data
point for TgG(Z)T121 (; n  21), TgG(Z)T121;
p53/ (; n  17), and TgG(Z)T121 ; PTEN/ (;
n  6) mice represents the death or sacrifice
of a mouse with terminal astrocytoma. Enlarged
spleens and lymph nodes were also present in
two TgG(Z)T121; p53/ mice.
ble 1). Western blotting of primary astrocytes also demonstrated p53 deficiency accelerates tumorigenesis by reducing the apo-
that levels of phosphorylated Erk1 and 2 were similar in normal ptosis evoked by Rbf inactivation (Lu et al., 2001; Symonds et
and tumor astrocytes (Figure 7K, Table 1). al., 1994). Since apoptosis reduction in astrocytomas correlated
with Akt activation, we tested the effect of both p53 and PTEN
heterozygosity on T121-induced astrocytoma development.PTEN, but not p53, heterozygosity accelerates
TgG(Z)T121 mice heterozygous for null alleles of either geneastrocytoma tumorigenesis
were generated in standard crosses. Surprisingly, p53 haplode-Inactivating mutations of PTEN, a negative regulator of Akt,
ficiency did not reduce the latency of astrocytoma (p  0.05,occur frequently in high grade human astrocytoma (50%) and
Wilcoxen rank test; Figure 5C). The average lifespan ofthus frequently coexist with mutations in the Rb pathway (see
Introduction). Mutation of p53 occurs at a much lower frequency TgG(Z)T121 mice was 180 days, while that of TgG(Z)T121;p53/
mice was 225 days. In most regions of the brain, morphologyand often appears at early stages (Reilly and Jacks, 2001; Maher
et al., 2001; Louis and Cavenee, 2001). In the CP tumor model, and cellularity were similar in TgG(Z)T121;p53/ and TgG(Z)T121
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Figure 6. Inactivation of the pRb pathway in
astrocytes predisposes to anaplastic astrocy-
toma
At 5–7 months of age, TgG(Z) T121 mice develop
anaplastic astrocytoma as indicated by histo-
logical features common to the human disease
(B–D, F and H). A–D are stained with H&E, E and
F with anti-GFAP, and G and H with anti-S100.
Positive immunoreactivity in E–H is blue. While the
brains of TgGZT121 mice are normal at all ages
(e.g., 6 months of age; A, E, and G), those of
compound mice contain widespread infiltrating
anaplastic cells (compare TgG(Z) T121 brains in
B, F, and H with respective controls in A, E, and
G). Furthermore, several pathological landmarks
of human astrocytoma, such as perineuronal (C)
and perivascular (D) satellitosis, are common. (A
neuron is marked by an asterisk in C; representa-
tive malignant cells are indicated by arrows in C
and D.) Brains with malignancy show widespread
GFAP positivity (F), including the presence of
GFAP-positive cell processes indicative of astro-
cytoma (F, inset). Anaplastic cells are also posi-
tive for S100 antigen (H). The black bar in A repre-
sents 20 M in A, B, D, G, H, and inset in F, 10 M
in C, and 200 M in E and F.
mice. Of interest, all TgG(Z)T121;p53/ mice developed olfac- nant astrocytoma. Brains displayed a diffuse increase in poorly
differentiated cells that were cytologically identical to thosetory bulb tumors consisting of giant cells that did not express
the astrocyte markers S100 and GFAP (not shown). The origin noted throughout the brains of age-matched TgG(Z)T121
controls. However, the hypercellularity in TgG(Z)T121;PTEN/of these tumors is currently unknown (see Discussion).
The lifespan of TgG(Z)T121 mice was significantly shortened brains was more marked, with many cells infiltrating the gray
and white matter, including with prominent perineuronal satel-when mice were heterozygous for a null PTEN allele (from an
average of 180 days to 72 days, p  0.01, Wilcoxen rank test; litosis and subpial growth. Mitotic activity was also present.
However, as with TgG(Z)T121 mice, neither microvascular prolif-Figure 5C). All TgG(Z)T121;PTEN/ mice (6 of 6) developed en-
larged crania by p7. When mice were terminally ill, brains contained eration nor necrosis was detected. TUNEL analyses of brains
from 17-day-old mice showed apoptosis levels to be reduceddiffuse astrocytic proliferation consistent with a diagnosis of malig-
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Table 1. Akt and Erk signal transduction pathways in astrocytoma
Activation in primary tumor cellsc
Genotype Age(D)a T121 P-Akt (Ser473) IHCb p-Erk(Thr202/Tyr204) IHCb p-Akt p-Erk1,2
G(Z)T121/; Cre/ 7* (w) ND ND
Cre/ 10* (w) ND ND
Cre/ 10* (w) ND ND
Cre/ 42 (w) BS; HCC ND  —
Cre/ 69 (w) Hy ND
Cre/ 94 (w) HCC; FCC ND  —
Cre/ 99 (w) Hy ND  —
Cre/ 113 (w) HCC ND  —
Cre/ 113 (w) BS; FCC ND  —
Cre/ 120 (w) ND SVZ
Cre/ 120 (w) ND ND — —
Cre/ 144** (w) ND ND
Cre/ 153 (w) M ND
Cre/ 154 (w) FCC ND
Cre/ 180 (w) Hy ND  —
Cre/ 216 (w) ND ND
Cre/ 225 (w) HCC; BS ND
Cre/ 253 (w) ND FCC
Cre/ 266 (w) BS ND
Cre/ 274 (w) HCC; HY; BS ND
Cre/ 286 (w) Th; M ND
a All mice except those marked with asterisks (see below) developed life-threatening anaplastic astrocytoma, and showed outward symptoms, e.g., bulged
head, and signs of morbidity when sacrificed.
b IHC was performed on sections through both hemispheres of each brain. However, step sections sampling the entire brain were not analyzed except for
two. Some positive regions might be missed.
c Tumor cells were isolated from brains and analyzed at passage two by Western blotting (Experimental Procedures).
* These mice were sacrificed when healthy.
** This mouse died while giving birth; otherwise, it didn’t show severe symptoms.
(w), widespread expression; ND, not detected; IHC, immunohistochemistry; BS, brain stem; HCC, hind cerebral cortex; Hy, hypothalamus; FCC, frontal
cerebral cortex; M, midbrain; Th, thalamus; SVZ, subventricular zone; , upregulated; —, unchanged (compared with WT primary astrocytes). Blank entries:
cells were not isolated from these mice.
in TgG(Z)T121;PTEN/ compared to TgG(Z)T121 mice (2.3% 2000; Stubdal et al., 1997). Using a mutant T121 defective in
binding the pRb proteins, we previously showed that this func-versus 4.2%, respectively). However, it is not yet clear whether
haploinsufficiency or PTEN inactivation is required for tumor tion was required for all T121 effects observed in vivo (Saenz-
Robles et al., 1994). Interestingly, astrocyte abnormalities areacceleration. Significantly, astrocytomas have not been re-
ported in PTEN/ mice, although they develop other tumor not induced upon inactivation of the Rb gene alone, either by
conditional deletion (Marino et al., 2000) or by the generationtypes beyond about 5 months of age (Di Cristofano et al., 1998;
Podsypanina et al., 1999; Suzuki et al., 1998). of chimeric mice harboring pRb-deficient cells (Maandag et al.,
1994; Williams et al., 1994). Thus, by comparison our results
indicate that functional redundancy/compensation occursDiscussion
among the pRb proteins in mouse astrocyte tumor suppression.
Evidence for redundancy among these proteins has also beenHere we demonstrate that inactivation of the pRb pathway in
astrocytes induces aberrant proliferation and extensive apopto- observed for murine retinal tumor suppression (Robanus-Maan-
dag et al., 1998), in murine development (Cobrinik et al., 1996;sis. With 100% penetrance, this condition progresses to malig-
nant anaplastic astrocytoma in adult mice. In more than 70% Lee et al., 1996), and in mouse embryo fibroblast cell cycle
regulation (Sage et al., 2000). Since mutation of the Rb geneof these tumors, areas of decreased apoptosis express acti-
vated Akt indicative of selective progression. As predicted by alone is frequent in human cancers, such compensation may
not exist in human cells, or may only be present in limited cellthis finding, tumorigenesis is accelerated in a PTEN/ back-
ground. Thus, the highly penetrant TgG(Z)T121 astrocytoma types.
model resembles the human disease with respect to both the
molecular targets and the ensuing pathology. This model should Predisposition to astrocytoma by pRbf inactivation
In founder transgenic mice expressing high levels of GFAP-prove useful for further mechanistic elucidation and possibly
for preclinical therapeutic testing. directed T121 expression, mice died perinatally with extensive
expansion of both neural precursor and anaplastic astrocyte
populations, with only the latter expressing T121. Using a condi-Redundancy in murine pRb tumor suppression
T121 inactivates all three pRb-related proteins (pRb, p107, and tional allele of T121 also expressed in astrocytes, early lethality
was circumvented, likely because of reduced levels of T121 ex-p130), an activity that requires direct interaction (T antigen amino
acids 105–114; Ewen et al., 1989; DeCaprio et al., 1989; Dyson pression and/or modifying effects of a distinct genetic back-
ground. In these mice, astrocyte-specific inactivation of the pRbet al., 1989) and an intact J domain (aa 1–82 (Sullivan et al.,
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Figure 7. Akt kinase is activated during astrocytomagensis
Fields from the same TgG(Z)T121 brain with terminal astrocytoma are shown in A–H. A–D are from one region, while E–H are from an adjacent area. Serial
sections were analyzed for activated Akt (P-Akt Ser473 level) (A and E), T121 expression (B and F), and PCNA (D and H) by IHC (blue staining), and apoptosis
by TUNEL (C and G, brown staining). Anaplastic astrocytes in the region expressing activated Akt (A–D) are proliferating based on PCNA staining and
express similar levels of T121, as do cells in the region not expressing activated Akt (E–H). However, apoptosis levels are reduced (compare C and G). Serial
sections of a brain from a 7-day-old TgG(Z)T121 mouse are shown in I and J. Activated Akt expression was not detected (I), although cells in the same
region expressed T121 (J). Western blotting analysis of primary astrocytes (K) also demonstrated that P-Akt Ser473 levels were increased in tumor cells (T 1-2)
relative to normal cells (C), while the level of total Akt and p-Erk1,2Thy183/Tyr185 were unchanged. Tumors (T) 1 and 2 contained regions that were positive for
activated Akt by IHC, while such regions were not detected in tumor 3.
proteins predisposed cells to malignant astrocytoma. Although ically, will provide an excellent model for exploring these aspects
of tumor evolution.the expansion of neural precursors was diminished in these mice
compared with TgGFAPT121 founders, this population remained Recent studies have shown that the activation of Ras signal-
ing pathways can predispose to glioblastoma or glioma-likeabnormally abundant. Whether this property contributes to the
development of astrocytoma is not clear. Experiments are un- lesions in mice. Somatic delivery of K-rasG12D and Akt genes
together (but not alone) into neural progenitor cells via retroviralderway to determine the role, if any, of such cell-cell interactions
in this disease. vectors induced glioblastoma (Holland et al., 2000). Transgenic
overexpression of H-RasV12 using the GFAP promoter also in-We examined the role of pRbf inactivation in astrocytoma
because this pathway is disrupted in nearly all human high- duced glioblastoma (Ding et al., 2001). Mice heterozygous for
both NF1 (a negative regulator of Ras) and p53 also developedgrade astrocytomas (see Introduction). Yet our results show
that inactivation of this pathway can constitute an initiating event glioblastoma with moderate penetrance in some genetic back-
grounds (Reilly et al., 2000). Low penetrance of astrocytomain the development of high-grade astrocytomas. It is possible
that stochastic inactivation of this pathway occurs in astrocytes was also observed in mice expressing a GFAP-v-src transgene
(Weissenberger et al., 1997). Although mutations in Ras, NF1,only as a result of selective pressures created by foregoing
initiating events. It may also be that tumors initiated by pRb AKT, or src have not been observed in sporadic human astrocy-
tomas, the EGF and PDGF tyrosine kinase receptors are fre-inactivation progress rapidly to high-grade disease. The
TgGZT121 mice, in which pRb inactivation can be induced somat- quently activated (Maher et al., 2001; Reilly and Jacks, 2001;
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Louis and Cavenee, 2001). One of the many downstream effects in the TRAMP model, where tumorigenesis is induced by SV40
of Ras signaling is the induction of cyclin D, a mediator of cdk4- large and small T antigens (Kwabi-Addo et al., 2001). In that
dependent pRb phosphorylation and inactivation (Sherr, 1996). case, loss of the wild-type PTEN allele was not detected, impli-
Epistasis experiments combining T121 and activated Ras alleles cating a dosage effect. We do not yet know whether
will determine whether pRb is an important downstream target TgG(Z)T121;PTEN/ astrocytomas undergo loss of the wild-
of Ras in the induction of astrocytoma. In TgG(Z) T121 mice, type allele or whether haploinsufficiency of PTEN alone causes
tumors have not spontaneously progressed to glioblastoma, yet acceleration of tumor growth. Given the diffuse nature of the
penetrance of the astrocytoma phenotype is 100%. It is possible tumors and the possibility for epigenetic inactivation, this as-
that widespread effects caused by pRb inactivation in a large sessment may not be straightforward. Thus, the PTEN status will
percentage of astrocytes preclude the development of the solid be assessed at the chromosomal, transcriptional, and protein
tumors associated with angiogenesis and necrosis. Mice may levels. In addition, analysis of TgG(Z)T121 mice harboring condi-
die with diffuse disease before mutations that facilitate solid tional PTEN null alleles will further address the role of PTEN
tumor growth develop or exert a significant effect. Induction of in astrocytoma progression. For example, reduction in PTEN
T121 expression in a limited number of astrocytes through so- dosage may accelerate tumor growth via apoptosis reduction.
matic introduction of Cre, as well as crosses onto a variety However, if PTEN loss further reduces apoptosis and/or influ-
of mutant backgrounds, should facilitate determination of the ences other aspects of tumor growth, selective pressure for
molecular and cellular requirements for progression to glio- PTEN inactivation could remain high.
blastoma. In the CPE tumor model previously examined, most T121-
induced apoptosis was p53-dependent, and in a p53/ back-
Cooperating events in astrocytoma development ground, tumor progression was accelerated and correlated with
The long latency between widespread T121 expression and the spontaneous p53 inactivation (Symonds et al., 1994; Lu et al.,
development of life-threatening astrocytomas in TgG(Z)T121 2001). Previously, wild-type T antigen (capable of inactivating
mice indicates that additional events could be involved. Astrocy- Rbf and p53) expressed under the GFAP promoter inducedtomas are diffusely infiltrating tumors, making it difficult to as- perinatal lethality (Danks et al., 1995) similar to that observed in
sess progression by regional morphological changes. However, TgGFAP-T121 founder mice, thus indicating that p53 inactivationin screening advanced astrocytomas for the activation of spe- may not alter the phenotype. Here, we show that the develop-
cific signal transduction pathways, we showed that 72% of the ment of diffuse astrocytoma in TgG(Z)T121 mice is indeed notastrocytomas contained regions of reduced apoptosis in which
accelerated in a p53/ background. Recently, oligoastrocy-
tumor cells expressed activated Akt. This result suggests that
toma and oligodendroglioma induced by somatic delivery of
astrocytes in which the pRb pathway is inactivated are under
PDGF was shown to be unaffected by p53 deficiency (Dai etselective pressure for deregulation of Akt, an event that may
al., 2001). In human astrocytomas, unlike many tumors, p53further facilitate astrocytoma development by a reduction in
mutation generally correlates with low-grade disease indicativeapoptosis. Further analysis of foci expressing activated Akt will
of an early rather than a progressive event (Louis and Cavenee,determine whether PTEN inactivation is the molecular basis for
2001; Reilly and Jacks, 2001; Maher et al., 2001).spontaneous Akt activation. Biological changes in addition to
Although the diffuse astrocytic phenotype appears unal-apoptosis reduction may also be present within these regions.
tered by p53 heterozygosity, olfactory bulb tumors uniquelySome astrocytomas examined did not contain detectable re-
develop in TgG(Z)T121 ;p53/ mice. The cellular origin of thegions of Akt activation. In this study, a limited number of sections
olfactory tumors is currently unknown; however, these tumorsfrom each brain were examined. Since the astrocytoma oc-
do not express common astrocytic markers. One possibility iscurred essentially throughout the brain and Akt activated regions
that, in combination with the periventricular expansion of neuralwere focal, a complete assessment would require a more exten-
precursors observed in TgG(Z)T121 mice, p53 haploinsuffi-sive analysis of the brain. Furthermore, as stated above, mice
ciency or inactivation aberrantly influences the neuronal cellsmay die of expansive astrocytoma before significant tumor pro-
that migrate along the rostral migratory stream into the olfactorygression occurs. It is also possible that alteration of distinct
bulb. Further analysis of these tumors and the role of p53 inpathways can lead to progression. Among the 4 p-Akt negative
their development is underway.brains, 2 showed upregulated p-Erk1,2 expression, indicating
Importantly, these studies address the cell specificity ofthat the MAP kinase pathway is induced, albeit at a much lower
tumorigenesis mechanisms. Together with previous studies, wefrequency than the Akt pathway. The full biological impact of
show that two diverse cell types, brain epithelium andthese changes remains to be determined.
astrocytes, respond similarly to disruption of the pRb pathway.PTEN is inactivated in 50% of human high-grade gliomas
In both cases, cells proliferate aberrantly, leading to extensiveby both LOH and epigenetic mechanisms (Reilly and Jacks,
apoptosis, and in both cases, this process predisposes cells to2001; Maher et al., 2001; Louis and Cavenee, 2001). Using
tumorigenesis. However, the events leading to tumor progres-a genetic approach, we show here that PTEN has a role in
sion appear to be distinct in the two systems. While the epithelialsuppressing astrocytomas initiated by pRbf inactivation. In a
tumors progress in a p53/ background and exhibit p53 inacti-PTEN/ background, TgG(Z)T121 mice developed high grade
vation (Lu et al., 2001), p53 heterozygosity does not appear toastrocytoma with significantly reduced latency. This study pro-
accelerate the development of diffuse anaplastic astrocytomas.vides direct evidence that PTEN mutation contributes to astro-
In contrast, these tumors are accelerated in PTEN/ mice. Incytoma development. Even in young TgG(Z)T121;PTEN/ mice,
each case, tumor progression is associated with a reduction inastrocyte apoptosis levels were reduced by about 50%, indicat-
apoptosis; however, the critical pathways involved appear toing a possible dose-dependent effect. PTEN haplodeficiency
was recently shown to accelerate prostate cancer progression be distinct.
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Experimental procedures (10 g/ml). Controls with single primary antibodies confirmed that secondary
antibodies did not crossreact with inappropriate primary antibodies.
Transgene construction, generation, and screening
of mice Primary astrocyte analysis
Brain pieces were digested in 0.05% Trypsin-EDTA (Gibco-BRL) at 37	C forTo construct the GFAP-T121 transgene, the T121 coding region was removed
30 min, followed by repeated trituration to form single cell suspensions.from pLE1137 (Chen et al., 1992) and ligated to the pGfa2 Lac-1 plasmid
Cells were plated in DMEM with N2 supplement, 10% FBS (Gibco-BRL). At(Dr. M. Brenner, Univ. Alabama) containing the 2.2 Kb human GFAP gene
passage two, 95% of the cells showed immunopositivity for GFAP (nottranscriptional regulatory sequences (Brenner et al., 1994). To construct the
shown). Immunoblotting followed the manufacturer’s protocol (Cell Signal-GZT121 transgene (Figure 1B), a 2.7 kb floxed lacZ cassette was removed
ing). Proteins were extracted from passage two cells, separated by 10%from pCLLA (Drs. Y. Li and H. Varmus, Sloan Kettering), blunt ended, and
SDS-PAGE electrophoresis and electrotransferred to PVDF membranes. Fil-ligated into the GFAP-T121 plasmid at the Kpn1 site (blunt ended). Both
ters were incubated with primary antibody (rabbit anti phosho-AktSer473, 9271;constructs were confirmed to be correct by sequencing. The EcoRV to Sal
1:1000) at 4	C overnight, washed extensively with TBST, incubated with1 transgene fragments were isolated and injected at a concentration of 4
HRP-conjugated goat anti-rabbit secondary antibody (1:3750), and thenng/ul into fertilized eggs from BDF1 mice as previously described (Chen et
detected with ECLTM (Amersham). After treating with 0.2 N NaOH, the sameal., 1992). Transgenic mice were screened using T121-specific primers 2 and
blots were used to detect the total level of Akt and the levels of phosphory-3 (Figure 1B and Chen et al., 1992). TgGZT121 transgenic lines were main-
lated Erk1, 2, consecutively (rabbit anti-Akt, 9272 and anti-phospho-Erk1,tained by crossing to nontransgenic BDF1 mice (Jackson Labs). To generate
2Thr202/Tyr204, 9101; 1:1000). All antibodies were from Cell Signaling.compound TgG(Z) T121 mice, TgGZT121 mice were crossed to Tg-Actin
Cre mice (FVB background, provided by Drs. M. Lewondonski and G. Martin,
AcknowledgmentsUCSF; Lewandoski and Martin, 1997). Primer sets 2 and 3 (Chen et al.,
1992), 1 and 3, and Cre-specific primers (Lewandoski and Martin, 1997)
We thank Eric Holland (Sloan Kettering, NY) for critical discussions andwere used to screen the doubly transgenic mice and to assay for cre-
technical advice. We thank the UNC Animal Models Core for microinjectionmediated deletion (Lewandoski and Martin, 1997). PCR conditions for prim-
of the GZT121 transgene, the UNC Lineberger Comprehensive Cancer Centerers 2 and 3 (Chen et al., 1992) and Cre primers (Lewandoski and Martin,
Histology Core for processing tissues used in this study, and the UNC1997) were as previously described. Conditions for primers 1 and 3 were
Division of Laboratory Animals for excellent animal care. This work was95	C 5
; 95	C 30

, 60	C 45

, 72	C 45

 for 35 cycles. Primer 1: TTC ATA
supported by NCI grants 1 R01 CA 46283 to T.V.D. and 5 U01 CA84314 toAAG CCC TCG CAT CCC AGG. TgG(Z) T121 mice were crossed with PTEN/ T.V.D. and D.N.L.
or p53 / mice to introduce the haplodeficency of either gene. Screening
of p53 and PTEN null alleles have been described (Lu et al., 2001; Di Cristo-
fano et al., 1998).
Received: October 2, 2001Southern hybridization analysis
Revised: February 14, 2002DNA extraction and Southern blotting were performed as described (Chen
et al., 1992). The T121-specific probe (a Hind III fragment containing only References
SV40 sequences) was isolated from pGFAP-T121. The control probe was a
Xba1 to EcoR1 fragment from the mouse PTEN gene isolated from plasmid
Brenner, M., Kisseberth, W.C., Su, Y., Besnard, F., and Messing, A. (1994).PTEN P1 (Di Cristofano et al., 1998) that detected a specific 8 kb Xba1 band
GFAP promoter directs astrocyte-specific expression in transgenic mice. J.from the PTEN locus. The T121 probe was hybridized first, and the filter was
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